comparemela.com
Home
Live Updates
Pfizer Reports Positive Data From Phase 3 Trial Of Talzenna/Xtandi Combo : comparemela.com
Pfizer Reports Positive Data From Phase 3 Trial Of Talzenna/Xtandi Combo
NEW YORK CITY (dpa-AFX) - Pfizer (PFE) Thursday reported positive results from the Phase 3 TALAPRO-2 study of Talzenna, an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with
Related Keywords
Dennis Riedl
,
Pfizer
,
Drug Administration
,
Priority Review
,
Reports
,
Positive
,
Data
,
Rom
,
Hase
,
Trial
,
Talzenna
,
Xtandi
,
Combo
,
comparemela.com © 2020. All Rights Reserved.